Gene Therapy Companies Among Top M&A Targets In 2020
Novo Nordisk And Gilead Tipped To Spend
Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.
You may also be interested in...
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.